Literature DB >> 15004323

Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dementia clinic.

J Riley McCarten1, Susan J Rottunda, Michael A Kuskowski.   

Abstract

The decline in the Mini-Mental State Exam (MMSE) over 2 years was assessed in males with Alzheimer's disease (AD; N = 136) seen in a dementia clinic. The average initial MMSE was 21.0 (SD+/-3.9; range 14--29) and declined 2.8 points (+/-4.7; range -17 to +6) over 2 years. The mode for change on the MMSE was 0 (N = 22) while the median fell between 2 and 3 points lost. Fifty-five of 136 patients (39.7%) had unchanged or better scores. There was no significant correlation between the initial MMSE and rate of change (r = -0.16; p = 0.06). While the progression of AD is quite variable from patient to patient, our data indicate that in most it is associated with little if any change in the MMSE even over 2 years. The MMSE is not an adequate tool to monitor change in the individual patient with AD.

Entities:  

Mesh:

Year:  2004        PMID: 15004323     DOI: 10.3233/jad-2004-6102

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

1.  Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons.

Authors:  Peter T Nelson; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Gregory A Jicha; Charles D Smith; Daron G Davis; John W Poduska; Ela Patel; Marta S Mendiondo; William R Markesbery
Journal:  Brain Pathol       Date:  2008-11-19       Impact factor: 6.508

2.  The transcript expression levels of HNRNPM, HNRNPA0 and AKAP17A splicing factors may be predictively associated with ageing phenotypes in human peripheral blood.

Authors:  Benjamin P Lee; Luke C Pilling; Stefania Bandinelli; Luigi Ferrucci; David Melzer; Lorna W Harries
Journal:  Biogerontology       Date:  2019-07-10       Impact factor: 4.277

3.  Cumulative effect of simvastatin, L-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer's disease.

Authors:  Elizabeth Degrush; Mohammed Salman Shazeeb; David Drachman; Zeynep Vardar; Clifford Lindsay; Matthew J Gounis; Nils Henninger
Journal:  Alzheimers Res Ther       Date:  2022-09-17       Impact factor: 8.823

4.  Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients.

Authors:  Eric R Braverman; Kenneth Blum; Uma J Damle; Mallory Kerner; Kristina Dushaj; Marlene Oscar-Berman
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

5.  Development and validation of a dementia screening tool for primary care in Taiwan: Brain Health Test.

Authors:  Ping-Huang Tsai; Jian-Liang Liu; Ker-Neng Lin; Chiung-Chih Chang; Ming-Chyi Pai; Wen-Fu Wang; Jen-Ping Huang; Tzung-Jeng Hwang; Pei-Ning Wang
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

6.  Astrocyte senescence may drive alterations in GFAPα, CDKN2A p14ARF, and TAU3 transcript expression and contribute to cognitive decline.

Authors:  Jed J Lye; Eva Latorre; Ben P Lee; Stefania Bandinelli; Janet E Holley; Nicholas J Gutowski; Luigi Ferrucci; Lorna W Harries
Journal:  Geroscience       Date:  2019-10-25       Impact factor: 7.713

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.